Introduction
============

Epilepsy is the most common chronic neurological disorders, affecting \~70 million individuals worldwide ([@b1-etm-0-0-7538]). Furthermore, \~0.5--1% of the pediatric population suffer from epilepsy ([@b2-etm-0-0-7538]) and approximately one-third of these patients are refractory to epilepsy medication ([@b3-etm-0-0-7538]). Valproic acid (VPA) is an anti-epileptic drug recommended by the National Institute for Health and Care Excellence guidelines as the first-line therapy for absence epilepsy ([@b4-etm-0-0-7538],[@b5-etm-0-0-7538]), and has been used for 50 years due to its efficacy and high tolerability ([@b6-etm-0-0-7538],[@b7-etm-0-0-7538]). Previous studies have indicated that approximately one-third of patients are non-responsive to VPA ([@b8-etm-0-0-7538],[@b9-etm-0-0-7538]), and the reason for this phenomenon remains elusive. Recently, Gesche *et al* ([@b10-etm-0-0-7538]) have demonstrated that resistance to VPA has a specificity of 100% regarding the identification of genetic generalized epileptic patients. Consequently, it is important to elucidate the mechanism underlying VPA efficacy and identify biomarkers predictive of VPA responses.

At present, two hypotheses for pharmaco-resistant epilepsy are commonly accepted, namely the multi-transporter hypothesis and the drug targets hypothesis. However, the mechanism of VPA resistance is distinct from that of other anti-epileptic drugs (AEDs). In fact, VPA is neither the substrate of multi-transporters, including P-glycoprotein, multi-drug resistant protein and breast cancer resistance protein, nor does it induce the expression of the multi-transporters in the brain ([@b11-etm-0-0-7538]--[@b14-etm-0-0-7538]). However, reported targets of VPA, including γ-aminobutyric acid receptor ([@b15-etm-0-0-7538],[@b16-etm-0-0-7538]), sodium channels and calcium channels, appear to not be involved in VPA resistance ([@b17-etm-0-0-7538]--[@b19-etm-0-0-7538]). These results suggest that the aforementioned hypotheses hardly explain the mechanisms of VPA resistance or efficacy.

Genome-wide gene expression profiling has been increasingly used to investigate pathogenetic mechanism and identify potential biomarkers for various human diseases ([@b20-etm-0-0-7538],[@b21-etm-0-0-7538]). RNA sequencing (RNA-seq) is a widely used method to study overall transcriptional activity and has a broad coverage. Previous studies employing the RNA-seq method led to the discovery of potential biomarkers for Alzheimer\'s disease and malignant glioma, including NeuroD6 and F11R, in brain tissues ([@b22-etm-0-0-7538],[@b23-etm-0-0-7538]). Fibronectin 1 and 12 other genes implicated in oxidative phosphorylation and glycolysis/gluconeogenesis pathways in the brain were identified as candidate critical factors for temporal lobe epilepsy, with and without hippocampal sclerosis ([@b24-etm-0-0-7538],[@b25-etm-0-0-7538]). However, few studies have addressed VPA efficacy and resistance, also due to the limited accessibility of brain tissue from VPA-treated patients.

Peripheral blood may be obtained non-invasively and is commonly used for studying biomarkers. Liew *et al* ([@b26-etm-0-0-7538]) have indicated that \~81.9% of the genes expressed in the brain were also expressed in the whole-blood microarray dataset. Borovecki *et al* ([@b27-etm-0-0-7538]) reported that the blood mRNA levels of specific target genes are associated with Huntington\'s disease severity and response to a histone deacetylase inhibitor. VPA is a histone deacetylase inhibitor ([@b28-etm-0-0-7538],[@b29-etm-0-0-7538]), potentially affecting, directly or indirectly, between 2 and 5% of all genes ([@b30-etm-0-0-7538]). A previous study reported that 11 genes were differentially expressed after a 3-month VPA treatment ([@b31-etm-0-0-7538]). In the present study, the mRNA expression profile in the blood of VPA responders and non-responders was analyzed after a treatment period of ≥1 year, to identify possible biomarkers for the prediction of VPA efficacy.

Materials and methods
=====================

### Patients

Subjects aged from 0 to 18 years were enrolled at the Children\'s Hospital of Fudan University (Shanghai, China) between July 2016 and May 2018. Each patient was evaluated according to the inclusion and exclusion criteria ([@b32-etm-0-0-7538]). The inclusion criteria were as follows: Pediatric patients diagnosed with epilepsy or an epileptic syndrome and administration of VPA for at least one year. The exclusion criteria were as follows: Patients with abnormal liver and kidney function, and patients who had developed infectious diseases, including upper respiratory infection and urinary tract infection, in the last three months.

Patients with a complete disappearance of seizures and a normal electroencephalogram were considered as VPA responders, while patients who continued to experience seizures were assigned to the non-responsive groups. Seizure types were identified according to the International League Against Epilepsy definition ([@b33-etm-0-0-7538]). Focal epileptic seizures were defined as events originating within networks limited to one hemisphere. Generalized epileptic seizures were conceptualized as originating at a certain point within, and rapidly engaging, bilaterally distributed networks ([@b34-etm-0-0-7538]).

### RNA preparation

Blood from three VPA responders and five non-responders without seizure for 12 h was collected in PAXgene blood RNA tubes and stored at −80°C until use. PAXgene tubes were stabilized for 2 h at room temperature. After centrifugation for 10 min at 3,000--5,000 × g at 4°C by using a swing-out rotor, the supernatant was removed by pipetting. Subsequently, 4 ml of RNase-free water were added to the pellet. Total RNA was extracted according to the instructions of the PAXgene Blood RNA kit (Qiagen), and the quality and quantity of total RNA were determined using a Qubit 2.0 (Thermo Fisher Scientific, Inc.) and a Bioanalyzer 2100 (Agilent Technologies).

### RNA-seq

Transcriptome sequencing libraries were prepared by using the TruSeq RNA LT V2 Sample Prep lit (Illumina, Inc.) and were qualified using the Qubit 2.0. Paired-end sequencing for 150 base pair was performed by an Illumina HiSeq 2500 instrument (Illumina, Inc.). All of the paired-end raw reads were quality-checked for low-quality bases and adapter sequences.

### Analysis of differentially expressed genes (DEGs)

Low-quality fractions and Illumina universal adapters were deleted by using Trim Galore v0.4.2 with the threshold of Q\<30. Fasta QC (version 0.11.5; Illumina, Inc.) was employed to assess the quality of the data. The paired-end sequencing reads were aligned to the reference genome (hg19), downloaded from the University of California Santa Cruz (UCSC) website (<http://hgdownload.soe.ucsc.edu/downloads.html>). Statistically significant expression changes between responders and non-responders were estimated using the Cuffilinks 2.2.1 software (<http://cole-trapnell-lab.github.io/cufflinks/install/>) with a threshold of 10 for NO TEST. Student\'s *t*-test was performed to calculate the P-value, while the false discovery rate controlled by the Benjamini-Hochberg procedure was used for determining the Q-value. Genes with a fold change of \>1 and P\<0.05 were defined as DEGs.

### Validation by reverse transcription-quantitative (RT-qPCR)

Changes in the mRNA expression of specific DEGs associated with epilepsy \[chemokine (C-C motif) ligand 3 and FOS\], exhibiting high fold changes, were validated by qPCR in 17 samples (including 6 VPA responders and 11 non-responders). Specific primers for selected genes were designed using Primer-BLAST (<http://www.ncbi.nlm.nih.gov/tools/primer-blast>). All samples were amplified in triplicate. qPCR amplifications were performed with the following cycling parameters: An initial hot start at 95°C for 5 min followed by 45 cycles of 95°C for 15 sec and 60°C for 30 sec. In order to normalize the qPCR results, GAPDH was included as the reference gene. The relative expression of genes was calculated based on the average quantification cycle (Cq) values across samples. Relative expression=2^{-\[(Cq\ gene\ of\ interest-Cq\ GAPDH\ of\ interest)\ non-responders\]-(Cq\ gene\ of\ interest-Cq\ GAPDH\ of\ interest)\ responders}}^ ([@b35-etm-0-0-7538]).

### Gene functions and pathways

Gene Ontology (GO) gene functions and biochemical pathways enriched by the DEGs were determined by using the web-based annotation tool DAVID v6.7 (<https://david-d.ncifcrf.gov/summary.jsp>) ([@b36-etm-0-0-7538]), providing GO terms in the categories biological process (BP), cellular component (CC), and molecular function (MF) and Kyoto Encyclopedia of Genes and Genomes pathways. P\<0.05 was used as the significance threshold.

### Construction and visualization of the protein-protein interaction (PPI) network

The PPI network based on the DEGs identified were constructed by using the STRING database (<https://string-db.org>), a pre-computed database wherein associations between proteins are assigned on the basis of high-throughput experiments, literature mining, gene fusion, co-occurrence, co-expression analysis, and also computational predictions, e.g. genomic meta-analysis. Interactions with a confidence score of 0.7 were considered for visualization by Cytoscape v3.4.0 (<https://cytoscape.org/>).

### Network module analysis

The Molecular Complex Deletion (MCODE) plugin for Cytoscape was used to analyze the network modules ([@b37-etm-0-0-7538]). Densely connected regions or clusters in the co-expression network were identified using the following parameters: Degree cut-off=2, k-core=2 and max. depth=100.

### Statistical analysis

DEGs analysis was performed by using Cuffilinks 2.2.1 software (cuffdiff, ttp://cole-trapnell-lab.github.io/cufflinks/install/). RT-qPCR data were analyzed using GraphPad Prism version 7.0 software (GraphPad, Inc.). Values were expressed as the mean ± standard error. Student\'s t-test was performed to analyze differences between VPA-responders and non-responders.

Results
=======

### Demographic data

A total of 8 pediatric patients with epilepsy were recruited, of which 3 were responders, while 5 were non-responders. All responders were males, while 3 of the non-responders were males and 2 females. The average age of the responders was 7.0±2.2 years and was not significantly different from that of the non-responsive group (4.8±1.8 years, P=0.47). Furthermore, no significant difference in the plasma VPA concentration was identified between the responsive and non-responsive groups (107.2±17.7 vs. 80.4±17.4, P=0.35; [Table I](#tI-etm-0-0-7538){ref-type="table"}).

### Comparative transcriptome profiling

A total of 1,153 genes were differentially expressed between responders and non-responders (P\<0.05; [Fig. 1](#f1-etm-0-0-7538){ref-type="fig"}). Of these DEGs, 389 had a \|Log 2 fold change\|≥1 and comprised of 227 upregulated and 162 downregulated genes. Among the 389 DEGs, 121 variations had a Q-value of \<0.05 and included 84 upregulated and 37 downregulated genes ([Fig. 2](#f2-etm-0-0-7538){ref-type="fig"}). The 20 most significantly upregulated and downregulated genes are listed in [Tables II](#tII-etm-0-0-7538){ref-type="table"} and [III](#tIII-etm-0-0-7538){ref-type="table"}, respectively.

Two genes (CCL3 and FOS), closely associated with epilepsy, were selected for validation by RT-qPCR, revealing significant differences in expression between VPA responders and non-responders, in accordance with the results of the RNA-seq. This indicated that the results obtained by the RNA-seq analysis were reliable ([Fig. 3](#f3-etm-0-0-7538){ref-type="fig"}).

### GO and pathway analysis

The GO and pathway enrichment analyses were performed for the 121 final DEGs, including 84 upregulated and 37 downregulated genes. In the GO category BP, the upregulated DEGs were significantly enriched in the GO terms 'cell cycle', 'immune response' and 'cell cycle process' ([Fig. 4A](#f4-etm-0-0-7538){ref-type="fig"}). In the category CC, the upregulated DEGs were enriched in the GO terms 'membrane-enclosed lumen', 'organelle lumen' and 'organelle lumen' ([Fig 4B](#f4-etm-0-0-7538){ref-type="fig"}), and in the category MF, they were enriched in the GO terms 'cytokine activity', 'chemokine activity' and 'chemokine receptor binding' ([Fig 4C](#f4-etm-0-0-7538){ref-type="fig"}). On the other hand, the group of downregulated DEGs was highly enriched in the GO terms 'response to wounding', 'defense response' and 'inflammatory response' in the category BP ([Fig 4D](#f4-etm-0-0-7538){ref-type="fig"}). In the category CC, the downregulated DEGs were highly enriched in the GO terms 'integral to membrane', 'intrinsic to membrane' and 'plasma membrane' ([Fig 4E](#f4-etm-0-0-7538){ref-type="fig"}), and in the category MF, they accumulated in the GO terms 'cation channel', 'iron ion binding' and 'IgE receptor activity' ([Fig. 4F](#f4-etm-0-0-7538){ref-type="fig"}).

The 121 DEGs were enriched in 22 pathways (P\<0.05), of which the Toll-like receptor signaling pathway, cancer pathways and cytokine-cytokine receptor interactions were the most represented ([Fig. 5](#f5-etm-0-0-7538){ref-type="fig"}).

### PPI network analysis and module identification

Analysis of the 121 DEGs by STRING and visualization with the Cytoscape plugin MCODE revealed 197 interactions, covering three modules ([Fig. 6](#f6-etm-0-0-7538){ref-type="fig"}). Of these, module 1 contained 73 interactions with 13 nodes (CDT1, PLK1, NUSAP1, RRM2, MKI67, CCNB2, HJURP, TPX2, CDCA8, TOP2A, BIRC5, KIF11, CDC45), module 2 included 21 interactions with 7 nodes (IFIT3, IFI44L, ISG15, RSAD2, IFI27, OASL, IFI44L), and module 3 contained 32 interactions with 12 nodes \[chemokine (C-X-C motif) ligand 9 (CXCL9), CCL3, CCL4, tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IRF1, HLA-DRB1, HLA-DRB5, IL8, PTGS2, FOS, HLA-DQA2)\] ([Fig. 7](#f7-etm-0-0-7538){ref-type="fig"}).

A literature review in PubMed confirmed that the function of CCL3, CCL4, CXCL9, TNF-*α*, IL-1β, and FOS is associated with epilepsy ([Table IV](#tIV-etm-0-0-7538){ref-type="table"}) ([@b38-etm-0-0-7538]--[@b44-etm-0-0-7538]).

Discussion
==========

Pharmaco-resistant epilepsy remains a major clinical issue with elusive underlying mechanisms. In the present study, a total of 1,153 DEGs between VPA responders and non-responders (P\<0.05) were initially identified. Of these genes, 123 upregulated and 60 downregulated genes fulfilled the criterion of P\<0.001. This number was higher than that in the study of Tang *et al* ([@b45-etm-0-0-7538]), which may be accounted for by the different methods used. In the latter study, oligonucleotide microarrays were employed, containing probe sets for more than 12,000 genes and ESTs. However, previous studies have concluded that microarray platforms suffer from technical issues including cross-hybridization, nonspecific hybridization and limited range of detection of individual probes ([@b46-etm-0-0-7538],[@b47-etm-0-0-7538]). As a result, genes with expression below or near the background level may exhibit increased variability and as such, calculated fold-changes for these genes may be difficult to detect with statistical significance. RNA-seq avoids such technical issues and exhibits a broader dynamic range. In the analysis of the current study, specific DEGs (dual specificity phosphatase 1, ribosomal protein S6 kinase A1 and aldehyde dehydrogenase 2 family member) reported by Tang *et al* ([@b45-etm-0-0-7538]) were also identified.

In the present study, most of the DEGs were implicated in the immune and inflammatory response, and associated with cytokine-cytokine receptor interactions, as also identified in epileptic patients by Floriano-Sánchez *et al* ([@b32-etm-0-0-7538]). Inflammation is increasingly recognized as an important pathogenetic factor in epilepsy. Evidence suggests the presence of all of the hallmarks of a chronic inflammatory state, i.e., infiltration of leukocytes, reactive gliosis, as well as overexpression of cytokines and their target proteins, in the brain of pharmaco-resistant epileptic patients and animal models ([@b48-etm-0-0-7538]). CCL3, CCL4 and CXCL9 are the chemokines that guide directional migration of leukocytes and have an important role in the inflammation of the central nervous system. Several studies have demonstrated increased mRNA and protein expression of CCL3, CCL4 and CXCL9 in the cortex and hippocampus of epileptic rats and drug-refractory patients ([@b49-etm-0-0-7538]--[@b51-etm-0-0-7538]). The present study revealed that the expression of CCL3, CCL4 and CXCL9 was higher in the blood of VPA non-responsive vs. responsive pediatric patients, which was consistent with the results obtained by Srivastava *et al* ([@b52-etm-0-0-7538]). The reason for the overexpression of CCL3, CCL4 and CXCL9 in the brain and blood of drug-refractory patients remains elusive. It has been reported that TNF-α and IL-1β induce the expression of CCL3 and CCL4 through NF-κB and activate inflammation via the mTOR signaling pathway ([@b41-etm-0-0-7538],[@b53-etm-0-0-7538]). Of note, VPA was demonstrated to reduce the amount of leukocytes and inhibit the expression of TNF-α ([@b54-etm-0-0-7538],[@b55-etm-0-0-7538]). The present study indicated that the mRNA levels of TNF-α, IL-1β, NF-κB and IL-1 receptor-associated kinase 2 (a regulator of TNF-α), were significantly higher in VPA non-responders than in responders, which suggested that CCL3 and CCL4 overexpression was associated with the high expression of TNF-α and IL-1β, and indicated that the transcriptional states of CCL3, CCL4, CXCL9, TNF-α and IL-1β are potential markers for monitoring the patients\' resistance to VPA.

Previous reports have revealed that increased TNF-α may result in the inhibition of cytochrome P450 family 2 subfamily D member 6 (CYP2D6) and CYP2C19 expression, and may results in the enhanced expression of CYP3A4 and CYP2C9 (the enzymes responsible for VPA metabolism in the brain) ([@b56-etm-0-0-7538]). Furthermore, TNF-α has been reported to induce the overexpression of transporter (P-gp), which is associated with AED efficacy ([@b57-etm-0-0-7538]). However, Feng *et al* ([@b58-etm-0-0-7538]) indicated that there was no difference in the plasma VPA concentration between responders and non-responders, suggesting that the role of TNF-α in the efficacy of VPA may be independent of its effects on drug metabolism and P-gp.

CCL3, CCL4, IL-1β and TNF-α are able to increase the permeability of the blood-brain barrier ([@b59-etm-0-0-7538],[@b60-etm-0-0-7538]), possibly resulting in their passage into the brain and cerebrospinal fluid ([@b61-etm-0-0-7538]). Furthermore, overexpression of CCL3 and TNF-α was identified to induce the influx of Ca^2+^ and to enhance the expression of N-methyl-D-aspartate receptor (NMDAR), leading to increased excitatory neurotransmission and contributing to the development of epileptic seizures and excitotoxicity ([@b62-etm-0-0-7538],[@b63-etm-0-0-7538]). Previous studies have demonstrated an association between NMDAR and the efficacy of AEDs. Zellinger *et al* ([@b64-etm-0-0-7538]) indicated that blocking the glycine-binding site of the NR2B subunit of NMDAR may increase the sensitivity to AEDs. Hung *et al* ([@b65-etm-0-0-7538]) confirmed that a specific mutation (−200 T\>G) of NR2B is associated with s sustained dosage of VPA. Therefore, it may be speculated that NMDAR functionally links CCL3, CCL4, IL-1β and TNF-α with VPA efficacy. However, further study is required for verification.

The protein expression of FOS, an immediate early gene and recognized biomarker of neuronal activity, is activated during spontaneous seizure ([@b66-etm-0-0-7538]--[@b68-etm-0-0-7538]). Previous studies have indicated that the expression of FOS rapidly increases 1.5 h after seizure stimulation by pentylenetetrazol and in amygdala-kindled seizures ([@b69-etm-0-0-7538]). However, the expression profile of FOS during seizures is complex and varies depending on the seizure type and status. FOS expression is increased in generalized seizure but not change in focal seizures. With respect to seizure status, high FOS mRNA expression was detected in rats at 1 h after the injection of kainic acid, while it tended to be low after 6 h ([@b70-etm-0-0-7538]). Furthermore, Madsen *et al* ([@b71-etm-0-0-7538]) identified a large increase in FOS expression at 2 h after a kindling stimulus, while after 18 h, the expression was lower than that observed upon a sham stimulation, and reached the control levels after 3 weeks. Of note, all plasma samples in the present study were collected during a non-seizure period which may account for the slightly decreased FOS expression.

In conclusion, the chemokines CCL3, CCL4, CXCL9, TNF-α and IL-1β may participate in processes associated with VPA resistance and serve as potential biomarkers for monitoring the efficacy of VPA. The study also revealed numerous critical pathways and sub-modules of potential pathogenetic relevance, deserving further investigation.
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![Heat map of differentially expressed genes between VPA responsive and non-responsive patients. The samples were clustered according to the VPA response. Blue and red color represent low and high levels of expression, respectively. VPA, valproic acid; Resp., responsive; Resi, resistant.](etm-18-01-0373-g00){#f1-etm-0-0-7538}

![Flow chart for the identification of differentially expressed genes. In total, 1,153 genes exhibited variations with P\<0.05, and 389 of these had a fold change of \>2. After P-value adjustment, 121 genes exhibited Q\<0.05. VPA, valproic acid; DEGs, differentially expressed genes.](etm-18-01-0373-g01){#f2-etm-0-0-7538}

![The 2^−∆∆Cq^ values of CCL3 and FOS in the valproic acid non-responsive (n=11) and responsive patients (n=6). (A) CCL3; (B) FOS. Cq, quantification cycle; CCL3, chemokine (C-C motif) ligand 3.](etm-18-01-0373-g02){#f3-etm-0-0-7538}

![Gene ontology enrichment analysis for the DEGs (Q\<0.05). (A-C) Terms enriched by the upregulated genes in the categories (A) biological process, (B) cellular component and (C) molecular function. (D-F) Terms enriched by the downregulated genes in the categories (D) biological process, (E) cellular component and (F) molecular function. IgE, immunoglobulin E; MHC, major histocompatibility complex; DEG, differentially expressed gene.](etm-18-01-0373-g03){#f4-etm-0-0-7538}

![Pathways enriched by the 121 DEGs (Q\<0.05). DEG, differentially expressed gene; Ig, immunoglobulin; RIG, retinoic acid-inducible gene.](etm-18-01-0373-g04){#f5-etm-0-0-7538}

![Protein-protein interaction network. Nodes with a degree of connectivity of 3--5, 5--10 and 10--13 were indicated in green, yellow and pink, respectively.](etm-18-01-0373-g05){#f6-etm-0-0-7538}

![The modules of the 121 DEGs (Q\<0.05). (A) Module 1; (B) module 2; (C) module 3. Pink and yellow nodes represent upregulated and downregulated genes, respectively.](etm-18-01-0373-g06){#f7-etm-0-0-7538}

###### 

Demographic data.

  Demographics           Responders   Non-responders                                                                                                                            
  ---------------------- ------------ ---------------- ------------- --------------- --------------- ------------- ------------- ------------- ------------- ------------------ ------
  Age (Years)            10.7         3                7.4           7.4 (3, 10.7)   9.6             4.8           8             0.3           1.3           4.8 (0.3, 9.6)     0.47
  Sex                    Male         Male             Male          --              Male            Female        Male          Female        Male          --                 --
  Seizure type           Unknown      Generalized      Generalized   --              Focal           Generalized   Generalized   Generalized   Generalized   --                 --
  AEDs                   VPA+TPM      VPA              VPA           --              VPA             VPA+LTG+OXC   VPA           VPA           VPA+LEV       --                 --
  Dose of VPA(mg/kg)     33.3         21.5             18.1          21.5            29.7            28.6          31.2          29.1          36.4          29.7               0.13
                                                                     (18.1, 33.3)                                                                            (28.6, 36.4)       
  Plasma concentration   139.1        77.9             104.6         104.6           56.7            62.0          148.2         57.3          77.7          62 (56.7, 148.2)   0.35
  (µg/ml)                                                                            (77.9, 139.1)                                                                              

AEDs, antiepileptic drugs; TPM, topiramate; LTG, lamotrigine; OXC, oxcarbazepine; LEV, levetiracetam; VPA, valproic acid.

###### 

Top 20 upregulated differentially expressed genes.

  Gene       Definition                                                                        Log2 fold change   P-value       Q-value
  ---------- --------------------------------------------------------------------------------- ------------------ ------------- -------------
  TSIX       TSIX transcript, XIST antisense RNA                                               7.59               5.00×10^−5^   9.00×10^−3^
  CXCL10     Chemokine (C-X-C motif) ligand 10                                                 5.99               5.00×10^−5^   9.00×10^−3^
  LILRA3     Leukocyte immunoglobulin-like receptor subfamily a (without tm domain) member 3   5.96               5.00×10^−5^   9.00×10^−3^
  FN1        Fibronectin 1                                                                     3.47               5.00×10^−5^   9.00×10^−3^
  GPR84      G protein-coupled receptor 84                                                     3.25               5.00×10^−5^   9.00×10^−3^
  PDK4       Pyruvate dehydrogenase kinase, isozyme 4                                          2.99               5.00×10^−5^   9.00×10^−3^
  SEMA6B     Sema domain. Transmembrane domain (tm) and cytoplasmic domain (semaphorin) 6b     2.74               5.00×10^−5^   9.00×10^−3^
  HLA-DRB5   Major histocompatibility complex class ii dr β 5                                  2.73               5.00×10^−5^   9.00×10^−3^
  PTGES      Prostaglandin E synthase                                                          2.73               5.00×10^−5^   9.00×10^−3^
  MYOM2      Myomesin 2                                                                        2.68               5.00×10^−5^   9.00×10^−3^
  CCL3       Chemokine (C-C motif) ligand 3                                                    2.60               5.00×10^−5^   9.00×10^−3^
  IL1B       Interleukin 1β                                                                    2.55               5.00×10^−5^   9.00×10^−3^
  IFI27      Interferon α-inducible protein 27                                                 2.32               5.00×10^−5^   9.00×10^−3^
  HJURP      Holliday junction recognition protein                                             2.17               5.00×10^−5^   9.00×10^−3^
  RRM2       Ribonucleotide reductase M2                                                       2.06               5.00×10^−5^   9.00×10^−3^
  CDCA5      Cell division cycle associated 5                                                  2.04               5.00×10^−5^   9.00×10^−3^
  FOLR3      Folate receptor 3 (γ)                                                             1.97               5.00×10^−5^   9.00×10^−3^
  TNF        Tumor necrosis factor                                                             1.89               5.00×10^−5^   9.00×10^−3^
  PLK1       Polo-like kinase 1                                                                1.83               5.00×10^−5^   9.00×10^−3^
  SEC14L2    SEC14-like 2 (*S. cerevisiae*)                                                    1.79               5.00×10^−5^   9.00×10^−3^

###### 

Top 20 downregulated differentially expressed genes.

  Gene        Definition                                                                                    Log2 fold change   P-value       Q-value
  ----------- --------------------------------------------------------------------------------------------- ------------------ ------------- -------------
  ARHGEF10    Rho guanine nucleotide exchange factor 10                                                     −3.33              5.00×10^−5^   9.00×10^−3^
  KCNG1       Potassium voltage-gated channel subfamily g member 1                                          −2.63              5.00×10^−5^   9.00×10^−3^
  FOS         FBJ murine osteosarcoma viral oncogene homolog                                                −2.20              5.00×10^−5^   9.00×10^−3^
  PAQR8       Progestin and adipoq receptor family member VIII                                              −2.06              5.00×10^−5^   9.00×10^−3^
  C21orf15    Chromosome 21 open reading frame 15                                                           −2.06              5.00×10^−5^   9.00×10^−3^
  PTGS2       Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)         −1.72              5.00×10^−5^   9.00×10^−3^
  HCAR2       Hydroxycarboxylic acid receptor 2                                                             −1.71              5.00×10^−5^   9.00×10^−3^
  IL8         Interleukin 8                                                                                 −1.67              5.00×10^−5^   9.00×10^−3^
  TGFA        Transforming growth factor α                                                                  −1.57              5.00×10^−5^   9.00×10^−3^
  HLA-DQA2    Major histocompatibility complex class II DQ α 2                                              −1.49              5.00×10^−5^   9.00×10^−3^
  FOSB        FBJ murine osteosarcoma viral oncogene homolog B                                              −1.47              5.00×10^−5^   9.00×10^−3^
  TNFRSF10C   Tumor necrosis factor receptor superfamily member 10c decoy without an intracellular domain   −1.46              5.00×10^−5^   9.00×10^−3^
  DUSP1       Dual specificity phosphatase 1                                                                −1.43              5.00×10^−5^   9.00×10^−3^
  RTN1        Reticulon 1                                                                                   −1.40              5.00×10^−5^   9.00×10^−3^
  TLR10       Toll-like receptor 10                                                                         −1.25              5.00×10^−5^   9.00×10^−3^
  KCNE3       Potassium voltage-gated channel Isk-related family member 3                                   −1.20              5.00×10^−5^   9.00×10^−3^
  THBD        Thrombomodulin                                                                                −1.19              5.00×10^−5^   9.00×10^−3^
  MYBL1       v-myb myeloblastosis viral oncogene homolog (avian)-like 1                                    −1.09              5.00×10^−5^   9.00×10^−3^
  ARFIP1      ADP-ribosylation factor interacting protein 1                                                 −1.38              1.00×10^−4^   1.60×10^−2^
  FCRL5       Fc receptor-like 5                                                                            −1.27              1.00×10^−4^   1.60×10^−2^

###### 

Functions of chemokine genes in epilepsy.

  Gene    Function                                                                         (Refs.)
  ------- -------------------------------------------------------------------------------- -------------------------------------------
  CCL3    Inhibition of systemic receptor leads to decrease in seizure activity            ([@b38-etm-0-0-7538],[@b39-etm-0-0-7538])
  CCL4    Inhibition of systemic receptor leads to decrease in seizure activity            ([@b38-etm-0-0-7538],[@b39-etm-0-0-7538])
  CXCL9   Immune-cell recruitment across the BBB                                           ([@b38-etm-0-0-7538])
  TNF     Activation of NF-κB and regulation of the process of post-seizure neurogenesis   ([@b40-etm-0-0-7538],[@b41-etm-0-0-7538])
  IL-1β   Induction of spontaneously recurring seizures                                    ([@b42-etm-0-0-7538])
  FOS     Regulation of CA3 neuronal excitability and survival                             ([@b43-etm-0-0-7538],[@b44-etm-0-0-7538])

BBB, blood-brain barrier; IL, interleukin; TNF, tumor necrosis factor; CXCL9, chemokine (C-X-C motif) ligand 9; CCL3, chemokine (C-C motif) ligand 3.
